COLUMBUS, Ohio — An executive who focused on cancer research at Ohio State University has left to become a vice president at Neoprobe Corp., according to a press release (pdf).
Frederick Cope is the new vice president of pharmaceutical research and clinical development at Neoprobe. The company, based in Dublin, Ohio, near Columbus, makes oncology and cardiovascular surgical and diagnostic products.
At OSU, Cope was the assistant director for research and head of program research development for the Comprehensive Cancer Center, The James Cancer Hospital and The Richard J. Solove Research Institute.
The Top Appointment Scheduling Software for Wellness Clinics
Scheduling software is helpful for wellness business owners in numerous ways. They get everything they need to create appointments, reschedule clients and track cancellations in one platform.
The company recently received a final $3 million installment(pdf) on a $13 million investment from Platinum-Montaur Life Sciences. Neoprobe received the last invesment after “favorable results” in a Phase 3 clinical trial of breast cancer patients treated with the company’s Lymphoseek product.
Lymphoseek helps in some procedures to pinpoint where fluid first drains from the lymph nodes in breast cancer or melanoma patients. The company also wants to resurrect its RIGScan CR product that works with colorectal cancer.
“Fred is joining us at an exciting point in our corporate development as we work through the pivotal clinical trials and prepare for the regulatory submissions to support marketing clearance for Lymphoseek and as we make visible progress in reinvigorating our development activities related to RIGScan CR,” stated David Bupp, Neoprobe’s president and chief executive officer.